Annals of Urologic Oncology (AUO, Ann Urol Oncol, p-ISSN: 2617-7765, e-ISSN: 2617-7773) is a peer-reviewed, international scientific journal committed to disseminating high-caliber research in the field of urologic oncology. The journal publishes original research addressing the molecular, cellular and clinical aspects of urologic tumors. The journal’s scope encompasses studies on risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment strategies aimed at improving patient outcomes in urologic oncology. The journal primarily focusses on three subjects: bladder, prostate and kidney cancer. Additionally, studies on adrenal tumors, testicular cancer, and carcinoma of the penis are also welcomed.
Indexing Google Scholar, ResearchGate, DOAJ
Current Issue Volume 8 Issue 2, 2025 >>
Editorial board
Editors-in-Chief:
Sanjay Gupta, Ph.D.----------Case Western Reserve University & UH Cleveland Medical Center, Cleveland, OH, USA.
Jae Y. Ro, Ph.D.---------------Houston Methodist Hospital and Weill Medical College of Cornell University, Houston, TX, USA. More >>
Primary bladder adenocarcinoma (PBA) is a rare malignancy comprising of only 0.5–2% of all bladder cancers and typically presents with nonspecific uri ...
Sonali Kar, Neeta Verma, Suren Kumar Das
CASE REPORT | 15 Sep 2025
Renal cancer (RC) ranks tenth among the most frequently diagnosed cancers and affects both men and women worldwide. This disease is a significant glob ...
Darragh Walsh, Callum Hayes
REVIEW | 02 Sep 2025
Previous data suggest that Angiotensin system inhibitors (ASIs) may exert antitumor effects; however, the findings remain controversial. Therefore, th ...
Shuenqin Hu, Xiuying Li
REVIEW | 28 Aug 2025
Kidney cancer, particularly clear cell renal cell carcinoma (ccRCC), has emerged as a paradigm for cancer metabolic reprogramming, exhibiting distinct ...
Elena Tena Edo
REVIEW | 07 Aug 2025
Prostate cancer, a leading cause of cancer-related mortality in men, often progresses to metastatic castration-resistant prostate cancer (mCRPC) despi ...
Xinliang Xu, Minna Liu
REVIEW | 23 Jul 2025
Prostate-specific antigen (PSA) testing, long used for prostate cancer screening, is limited by poor specificity (~25%), leading to unnecessary biopsi ...
Fan Li, Xian Zhang
REVIEW | 31 Jul 2025
Submit Manuscript
